Merck & Co.
Search results
Sinovac-CoronaVac. Pfizer-BioNTech, Moderna and Novavax have successfully obtained full registration for their vaccines. Sinovac-CoronaVac vaccine continues to be included under the National Vaccination Programme (NVP)* until 30 September 2024.
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.
The Pfizer-BioNTech / Comirnaty COVID-19 vaccine protects against COVID-19. The vaccine contains messenger RNA (mRNA) which helps your immune system to produce protection.
Aug 18, 2022 · This article provides a summary of the interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19 issued by WHO Strategic Advisory Group of Experts on Immunization (SAGE).
Both Pfizer-BioNTech/Comirnaty and Moderna/Spikevax COVID-19 vaccines are mRNA vaccines. As mRNA vaccines are not live vaccines, they are biologically unlikely to adversely affect breastfed babies. In addition, the breast milk of vaccinated mothers may help to protect their babies from COVID-19 due to antibodies in breast milk.
Dec 30, 2020 · The Health Sciences Authority authorised the Pfizer-BioNTech COVID-19 vaccine, based on the following assessment: It has a high vaccine efficacy of 95% in preventing symptomatic COVID-19 disease in vaccinated persons aged 16 years and older.
1 day ago · The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older Recommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineages Doses will be ready to ship to applicable EU member ...
